This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma
LTZ Therapeutics, Inc.
LTZ Therapeutics, Inc.
Verismo Therapeutics
University of Arizona
Mayo Clinic
University of Nebraska
Ipsen
Case Comprehensive Cancer Center
University of Maryland, Baltimore
M.D. Anderson Cancer Center
Masonic Cancer Center, University of Minnesota
University of Louisville
Dana-Farber Cancer Institute
Regeneron Pharmaceuticals
Regeneron Pharmaceuticals
University of Alabama at Birmingham
Morphotek
Fred Hutchinson Cancer Center
Cellerant Therapeutics
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Rutgers, The State University of New Jersey
Boston Medical Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Novartis
National Cancer Institute (NCI)
Duke University
National Cancer Institute (NCI)
Northwestern University
Northwestern University
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Case Comprehensive Cancer Center
Case Comprehensive Cancer Center
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins